Akero Therapeutics Inc.

The organisation pursues advanced therapeutic strategies targeting hepatic fibrogenesis and the structural remodelling of liver tissue. Research activities focus on understanding the cellular and molecular mechanisms that drive extracellular matrix deposition in the liver, with particular attention to the transition from reversible fibrosis to irreversible cirrhosis. The sponsor investigates interventions designed to modulate stellate cell activation and collagen synthesis pathways.

• Liver Fibrosis Regression and Stabilisation
• Cirrhotic Disease Management
• Hepatic Stellate Cell Biology

Clinical investigations examine biomarkers of fibrosis progression and therapeutic endpoints related to histological improvement in liver architecture. The research emphasises identifying patients at risk for advanced fibrotic disease and developing treatments that can meaningfully alter the natural history of chronic liver conditions.

Akero Therapeutics Inc. explores the systemic metabolic disturbances that frequently accompany chronic liver disease. The sponsor's research addresses dyslipidaemia, insulin resistance, and glucose metabolism disorders that contribute to both hepatic and cardiovascular pathology. Clinical programmes investigate the bidirectional relationship between liver disease and metabolic syndrome, examining how hepatic dysfunction influences systemic metabolic homeostasis.

• Lipid Metabolism and Dyslipidaemia
• Insulin Sensitivity and Glucose Regulation
• Cardiovascular Risk in Metabolic Liver Disease

The organisation's investigations encompass the metabolic complications that increase morbidity and mortality in patients with fatty liver disease, including atherosclerotic cardiovascular disease risk factors. Research efforts focus on therapeutic approaches that address multiple components of the cardiometabolic disease spectrum simultaneously.